Open Access

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

Nikolaos Gouvas
Nikolaos Gouvas
, 
Telenia Kalambaliki
Telenia Kalambaliki
, 
Alexandra Voutsina
Alexandra Voutsina
, 
Zenia Saridaki
Zenia Saridaki
, 
Maria Tzardi
Maria Tzardi
, 
Aristea Kalykaki
Aristea Kalykaki
, 
Maria Sfakianaki
Maria Sfakianaki
, 
Athanasios Athanasiadis
Athanasios Athanasiadis
, 
Evaghelos Xynos
Evaghelos Xynos
, 
Ioannis Boukovinas
Ioannis Boukovinas
 and 
John Souglakos
John Souglakos
   | Jul 12, 2019
Forum of Clinical Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Jul 12, 2019
Page range: 31 - 36
Received: Mar 22, 2018
Accepted: Mar 17, 2019
DOI: https://doi.org/10.2478/fco-2018-0005
Keywords
© 2018 Nikolaos Gouvas, Telenia Kalambaliki, Alexandra Voutsina, Zenia Saridaki, Maria Tzardi, Aristea Kalykaki, Maria Sfakianaki, Athanasios Athanasiadis, Evaghelos Xynos, Ioannis Boukovinas, John Souglakos, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Introduction

Several studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent prognostic factor for the response to treatment with anti-EGFR moAbs. The aim of this observational study was to assess the feasibility of the KRAS/NRAS mutational analysis in patients with metastatic colorectal cancer in Greece and to identify any correlations with known clinical characteristics and histopathologic features.

Methods

From January 2014 until September 2014 all patients registered to the GIC-SG database with newly diagnosed metastatic disease from colon or rectal cancer were included and tumor samples were analyzed for kras/nras mutations in 9 different certified laboratories in Greece.

Results

Samples from 510 patients were analyzed. Mutations’ distribution was as follows: 173 (33,9%) KRAS exon 2, 10 (2%) KRAS exon 3, 25 (4,9%) KRAS exon 4, 22 (4,3%) NRAS exon 2, 11 (2,2%) NRAS exon 3 and 3 (0,6%) NRAS exon 4. The only factor significantly associated with RAS mutational status was primary tumor location, with right sided tumors exhibiting higher rates of mutations.

Discussion

The incidence and distribution of KRAS or NRAS exon 2-4 mutations are in accordance with those reported in the literature. The most significant clinical or pathological parameter revealed from the analysis is the location of the primary tumor.

eISSN:
1792-362X
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology
Journal RSS Feed